In Brief Marcus et al. find that cGAMP produced by tumor cells triggers the activation of the STING pathway in immune cells within the tumor microenvironment. This leads to interferon production by these cells, which in turn activates NK cell anti-tumor immunity.
INTRODUCTION
Natural killer (NK) cells are cytotoxic lymphocytes that can directly kill infected and transformed cells and shape adaptive immune responses by secreting cytokines. NK cell recognition of target cells is mediated by the balance of signaling conveyed by germline-encoded activating receptors for stress-induced or virus-encoded ligands on target cells (Lanier, 2005; Marcus et al., 2014; Yokoyama and Plougastel, 2003) and inhibitory receptors that engage MHC I molecules (K€ arre, 2008) .
In vivo, NK cells can reject sensitive tumor cells efficiently, but ex vivo, resting NK cells obtained from healthy animals or donors often exhibit relatively low cytotoxicity (Diefenbach et al., 2001; Glas et al., 2000; Raulet, 2004) . The mechanisms whereby NK cells acquire strong effector activity in vivo against tumor cells are not well defined. Acquisition of strong effector activity (''priming'') can be conferred by infections, cytokines (e.g., type I interferon [IFN] , interleukin-15 , and IL-12), ligands for pattern-recognition receptors (e.g., double-stranded RNA), and vaccination with irradiated tumor cells (Chaix et al., 2008; Diefenbach et al., 2001; Glas et al., 2000; Guia et al., 2008; Mortier et al., 2009) . Whether these pathways are relevant in priming NK cell activity in the tumor setting is unclear.
Because IFNs can prime strong effector activity in NK cells, the cGAS-STING pathway is an attractive candidate in considering the activation of NK cells to exert anti-tumor activity. The cGAS-STING pathway mediates cellular immune responses to cytosolic DNA (Chen et al., 2016b; Ishii et al., 2006; Stetson and Medzhitov, 2006) . The cGAS enzyme, when bound by cytosolic DNA, catalyzes the synthesis of a cyclic-GMP-AMP dinucleotide called 2ʹ3ʹ-cGAMP (Ablasser et al., 2013a; Diner et al., 2013; Gao et al., 2013b; Wu et al., 2013; Zhang et al., 2013) . cGAMP binds and activates the endoplasmic reticulum (ER)-resident adaptor protein STING (stimulator of interferon genes protein) (Ablasser et al., 2013a; Diner et al., 2013; Gao et al., 2013c; Ishikawa et al., 2009; Zhang et al., 2013) , which leads to the downstream activation of the transcription factors IFN regulatory factor 3 (IRF3) and nuclear factor kB (NF-kB) (Chen et al., 2016b ) and the expression of type I IFN, IFN-responsive genes, and various other chemokines and cytokines (e.g., CCL5). The cGAS-STING pathway plays an important role in immune responses to viral infections (Chen et al., 2016b; Ishii et al., 2006; Stetson and Medzhitov, 2006) , and emerging evidence in both tumor transfer models and autochthonous models of cancer suggests a role for this pathway in anti-tumor immunity as well (Brzostek-Racine et al., 2011; Gasser and Raulet, 2006a; H€ artlova et al., 2015; Lam et al., 2014; Ohkuri et al., 2014; Woo et al., 2014; Zhu et al., 2014) .
It has been suggested that DNA leaking from tumor cell nuclei or from dying tumor cells can activate STING in host cells and induce T-cell-mediated anti-tumor responses (Klarquist et al., 2014; Ohkuri et al., 2014; Woo et al., 2014) . The model suggests that tumor-derived DNA accesses the cytosol of host antigenpresenting cells (APCs) by some unknown mechanism, whereby it triggers the cGAS-STING pathway and causes IFN production.
IFN causes maturation of APCs and enhances priming of T cells against the tumor. Because STING activation and IFN production can potentially prime strong effector activity in NK cells, the cGAS-STING pathway could be important in the activation of intra-tumoral NK cell responses.
Here, we found that spontaneous in vivo NK cell rejection of tumor cells, but not untransformed cells, depends critically on the cGAS-STING pathway. cGAS in tumor cells was active under steady-state conditions and could elicit spontaneous NK cell 
RESULTS

Sting gt/gt Mice Are Susceptible to
Tumors Independently of Effects on T and B Cells STING is important for inducing T cell responses against tumors (Woo et al., 2014) . To test whether STING plays a role in anti-tumor responses against tumors that are poorly recognized by T cells, we challenged mice with the TAP2-deficient RMA-S lymphoma and the poorly immunogenic B16-BL6 melanoma. RMA-S lymphoma cells were rejected by wild-type (WT) mice but grew progressively in STING-deficient (Sting gt/gt ) mice ( Figure 1A ). Rejection of RMA-S cells was also impaired in mice deficient in IRF3, which acts downstream of STING ( Figure 1B mice were significantly more susceptible to RMA-S and B16-BL6 tumor challenge than Rag2 À/À mice ( Figures 1E and 1F ).
In response to other transplanted tumors, T cells play an important role, but if the cells are NK sensitive, NK cells can also participate in rejection. For example, T cells play an important role in rejecting the MC38 colon carcinoma, but these cells are also NK sensitive as a result of the expression of ligands for NKG2D and other activating receptors on NK cells. In order to circumvent the T cell response and more clearly reveal the NK cell response, we once again employed mice on the Rag2 background. Rag2
Sting gt/gt mice were significantly more susceptible than
Rag2
À/À mice to challenge with MC38, thereby establishing the relevance of host STING in yet another tumor model ( Figure 1G ).
STING Induces NK-Cell-Mediated Anti-tumor Responses Both RMA-S and B16-BL6 are sensitive to NK cells in vivo, suggesting that STING can induce NK cell responses. STING-mediated protection against RMA-S and B16-BL6 tumors ( Figures  2A and 2C ) was abolished by antibody-mediated depletion of NK cells ( Figures 2B and 2D ). These analyses confirmed that spontaneous STING-mediated protection against RMA-S and B16-BL6 tumors requires NK cells but not T cells or B cells. Furthermore, host STING played no role in tumor growth when tumors were NK insensitive, as in the case of RMA, the major histocompatibility complex I (MHC I)+ counterpart of RMA-S (Figure 2E) . Thus, the impact of STING in these responses is mediated through NK cells and not through the cytostatic effects of IFN or some other NK-independent mechanism. Despite expression of MHC I, RMA cells are rendered NK sensitive when transduced with an NK-activating ligand, RAE-1ε, a ligand for the NKG2D receptor (Diefenbach et al., 2001) . Notably, rejection of RMA-RAE-1ε cells was also dependent on host STING expression ( Figure 2F ). Therefore, STING is required for the rejection of tumor cells that are sensitive to NK cells as a result of MHC I deficiency or expression of activating ligands. These findings suggest a role for STING against many tumor types, given that NKG2D ligand expression and NK sensitivity are common features of tumors (Raulet et al., 2013 Figure 4C ) but did respond to stimulation with 2ʹ3ʹ-cGAMP ( Figure 4D Figure 5H ). Thus, type I IFN activates NK cells both directly and indirectly. We stained NK cells for STING expression and found that a subset of them did express STING ( Figure 5I ), raising the possibility that STING acts intrinsically in NK cells. We therefore tested whether NK-cell-intrinsic STING is necessary for NK cell activation induced by 2ʹ3ʹ-cGAMP. We adoptively transferred splenocytes from Sting gt/gt mice into CD45.1 mice and challenged the mice with 2ʹ3ʹ-cGAMP. CD69 expression revealed that 2ʹ3ʹ-cGAMP injections resulted in equivalent activation of WT and Sting gt/gt NK cells ( Figure 5J ), demonstrating that NK-cell-intrinsic STING signaling is dispensable for NK cell activation and that STING must act via other cell type(s).
To address which cells respond to 2ʹ3ʹ-cGAMP, we injected the cyclic dinucleotides directly into RMA-S tumors and then 1 hr later, harvested and incubated the tumors for an additional 5 hr in the presence of Golgi transport inhibitors, allowing for Figure 5K ), suggesting that these cells play a role when 2ʹ3ʹ-cGAMP is injected into tumors. B cells were largely absent from these tumors but could play a role in different tumors in response to 2ʹ3ʹ-cGAMP. Indeed, when 2ʹ3ʹ-cGAMP was injected intraperitoneally, intracellular IFN-b was detected in peritoneal B cells when examined ex vivo. Together, our results suggest that multiple cell types are capable of responding to 2 0 3 0 -cGAMP and that the relevant cells for a given response can be context dependent ( Figure 5L ).
cGAS Is Specifically Active in Tumor Cells
To test directly whether cGAS in tumor cells is required for tumor rejection mediated by host STING, we used CRISPR/Cas9 technology and two gRNAs concurrently to delete the first exon of Cgas in B16-BL6 tumor cells without stably introducing any other marker proteins in the cells. cGAS-deficient B16-BL6 cells failed to respond to DNA stimulation given that they did not increase expression of Ifnb, Ccl5, or Ifit1 ( Figure S2 ). In the absence of DNA stimulation, WT cells showed significant steady-state expression of cGAS and STING target genes Ccl5 and the interferon-inducible Ifit1, and this expression was significantly reduced in cGAS-deficient B16-BL6 cells, arguing that cGAS is partially active without purposeful induction in the WT tumor cells ( Figures 6A and 6B ). Ccl5 and Ifit1 expression was restored when the mutant tumor cells were transduced with WT cGAS but not enzymatically inactive cGAS (G198A/S199A). Both WT and mutant transduced cGAS were expressed at similar levels to each other but had higher expression than endogenous cGAS. Compared with expression in non-transduced cells, the increased expression of WT cGAS, but not of mutant cGAS, in transduced cells augmented Ccl5 and Ifit1 expression. Steady-state activation of the cGAS-STING pathway was also observed in human monocytic cell line THP1, whereby THP1 TMEM173 À/À cells expressed lower levels of IFIT1 and CXCL10 than THP1 WT cells ( Figures S3A and S3B ). These data suggest that cGAS is active in both tumor cell lines in the absence of exogenous DNA stimulation, which results in low but detectable constitutive expression of IFN-inducible genes. In contrast to the results with the tumor cells, splenocytes, bone marrow cells, lung cells, and liver cells from WT and cGAS-deficient mice expressed similar levels of Ccl5 and Ifit1 . These data indicate that constitutively active cGAS is a distinguishing feature of tumor cells. One possible explanation for the constitutive activation of the cGAS-STING pathway is that it is activated by DNA damage in the tumor cells, as was previously suggested (Ho et al., 2016; Lam et al., 2014; Shen et al., 2015) . Indeed, induction of DNA damage in B16 cells by chemotherapy drug ARA-C led to increased cGAS-dependent secretion of type I IFN ( Figure S3I ).
Expression of cGAS by Tumor Cells Is Crucial for Tumor Rejection
We tested the impact of cGAS expression on tumor rejection in vivo. Remarkably, cGAS-deficient tumor cells were not rejected in a STING-dependent fashion in vivo, whereas WT tumor cells were partially rejected as before (Figures 6E and 6F) . Restoration with WT cGAS restored the STINGdependent tumor rejection response, whereas restoration with catalytically inactive cGAS did not ( Figures 6G-6H and Figures  S3J and S3K) , confirming that the defect was due to differences in cGAS enzymatic activity and not to other clonally variable properties of the tumor cells. Together, these data indicate that the NK-mediated rejection of B16-BL6 tumors requires active cGAS in tumor cells and STING expression in host cells.
CGAS Expression Correlates with Immune Activation and Improved Survival in Melanoma
We sought to evaluate the clinical relevance of our findings by analyzing cGAS expression in tumors with publicly available data from The Cancer Genome Atlas (TCGA). Because our find- ings suggest a role for CGAS expression in tumors in inducing anti-tumor responses, we focused on melanoma, which tends to be a relatively immunogenic tumor type. We proceeded to look for gene expression relationships consistent with the induction of immune activation by cGAS expression. As a control comparison, we examined pairs of genes that are known to be coexpressed, such as CD3E and CD3D, which did indeed display a significant although imperfect correlation ( Figure 7A ). Given that CGAS-induced genes are also induced by other upstream sensors, we opted to use cGAS expression as a surrogate marker for cGAS activation on the basis of the reasoning that higher cGAS expression leads to a stronger activation of the pathway. Immune activation was quantified on the basis of the expression of several genes, including CD69, IFNG, TNF, GZMA, GZMB, and IFIT1. We found strong correlations between cGAS expression levels and expression of immune-activation genes ( Figure 7B and Figure S4 ). We could not assess NK cell activation directly because there are no immune activation markers that are specific to NK cells. We could, however, quantify NK cell infiltration by examining expression of several genes that are preferentially expressed by NK cells including: KIR2DL4, NCR1, KLRD1, KLRC1, KLRC2, KLRC3, KLRC4, KLRB1, and KLRK1. There was a significant correlation between cGAS and expression levels of the various NK cell receptors ( Figures 7C-7D and Figure S5 ).
We then asked whether increased cGAS expression is associated with expression of ligands that render cells NK sensitive. There was a significant correlation between cGAS expression and expression of the NKG2D ligands ULBP1 and ULBP3 (Figures 7E and 7F ), in accordance with an earlier report that showed that cGAS-STING activation can lead to expression of NKG2D ligands (Lam et al., 2014) . Finally, in melanoma patients, we demonstrated a significant correlation between cGAS expression levels and survival and between NK cell receptor (including NCR1) expression levels and survival . These data are consistent with a role for cGAS in the induction of anti-tumor responses in melanoma patients in accordance with our model. 
DISCUSSION
Two major conclusions can be derived from our findings. First, NK-dependent rejection of tumor cells is largely reliant on the activation of STING in non-tumor cells, at least in some cases. Second, steady-state activation of cGAS in tumor cells rather than cGAS activation in host cells is required for NK cell responses against tumors, suggesting that tumorderived cGAMP is responsible for STING activation and could be transferred to non-cancerous cells to activate the response. Thus, aberrant cGAS activation in tumors boosts anti-tumor immune responses. Notably, rejection of normal MHC-I-deficient bone marrow cells by NK cells did not require host STING expression, nor did T-cell-mediated skin allograft rejection (Woo et al., 2014) . These findings support the conclusion that the immunogenicity of tumor cells in both the NK and T cell responses could be amplified by the cGAS-STING pathway, although it remains possible that other differences between these tumor cells and normal cells or in the experimental protocols could account for the different outcomes.
The evidence that the cGAS-STING pathway underlies NK cell responses to tumors provides a new foundation for the decadesold field of natural cytotoxicity to tumors (Herberman et al., 1975; Kiessling et al., 1975 (Woo et al., 2014) , and it will be interesting to address whether tumor or host cGAS is similarly necessary for such T cell responses. It has previously been proposed that tumor cells activate the cGAS-STING pathway in vivo through the transfer of tumor cell DNA into host cells (Klarquist et al., 2014; Ohkuri et al., 2014; Woo et al., 2014) , although the mechanism whereby tumor DNA might access the cytosol and the causal relationship between DNA transfer and STING activation have not been established. The DNA transfer model predicts that cGAS, like STING, is required in host cells, contrary to our results. Instead, our results suggest that cGAMP is produced in tumor cells and could be transferred to host cells to trigger STING, resulting in the production of cytokines (such as type I IFN), which are known to enhance NK cell cytotoxicity. cGAMP transfer can occur in the context of viral infection, at least in an in vitro setting, through a variety of mechanisms, including transfer through gap junctions, transfer through viral particles, and transfer via membrane fusion (Ablasser et al., 2013b; Gentili et al., 2015; Xu et al., 2016) . In vivo, cGAMP transfer through gap junctions between tumor cells and astrocytes promotes brain metastases, although the underlying mechanisms are not clear (Chen et al., 2016a) , but evidence supporting a role for cGAMP transfer in vivo in inducing immune responses is lacking.
Our data suggest that cGAMP is transferred from tumor cells to host cells to initiate the response. STING can be activated in response to DNA damage, which could explain why cGAMP is produced in tumor cells. DNA damage and activation of the DNA damage response are a hallmark of cancer (Gasser and Raulet, 2006b; Hanahan and Weinberg, 2000) , and some tumor cell lines, such as YAC-1, EmM1, TRAMPC2, DU145, and PC-3, contain detectable cytosolic DNA (Ho et al., 2016; Lam et al., 2014; Shen et al., 2015) and spontaneously produce cytokines in culture in a STING-dependent manner. Together with our finding that the cGAS-STING pathway is constitutively active in B16 and THP1 cells, these data suggest that constitutive activation of the cGAS-STING pathway is fairly common and most likely occurs in many tumors. We propose that genomic abnormalities and the consequent activation of the DNA sensing pathway help to mark these cells as abnormal and trigger cGAS in tumor cells. This leads to STING activation in host cells and eventually mobilizes a sufficiently potent NK cell response to reject the tumors (completely or partially depending on the system). This proposal would establish cGAS activation as a distinguishing characteristic of tumor cells and would explain why rejection of non-transformed MHC-I-deficient bone marrow (H) Kaplan-Meier plot of melanoma patient survival; patients are segmented by KIR2DL4 expression (highest and lowest thirds). All data were obtained from The Cancer Genome Atlas (TCGA). For correlations of expression, statistical significance was assessed with the Spearman coefficient. For survival analysis, statistical significance was assessed with the log-rank test. cells does not require host STING. It is plausible that rejection of non-transformed cell grafts requires only weak NK cell activity that is independent of host STING activation, whereas rejection of growing tumor cells requires a more potent or sustained response that depends on factors downstream of host STING.
Our model positions cGAS expression in tumors as a major determinant of tumor immunogenicity. Interestingly, cGAS is inactivated in certain tumors (Xia et al., 2016a; Xia et al., 2016b) . Loss of cGAS from tumor cells might be a mechanism by which tumors evolve to escape the cGAS-STING-dependent immune response we describe here. It is difficult to envisage, however, how loss of cGAMP production in one cell would provide a fitness advantage to that cell if tumor cells nearby continued to produce cGAMP. Alternatively, loss of cGAS expression by tumor cells could provide cell-intrinsic benefits to tumor cells, e.g., permit the tumor cell to circumvent senescence (Gl€ uck et al., 2017; Yang et al., 2017) or prevent immunostimulatory NKG2D ligand expression (Lam et al., 2014) . Regardless, our results imply that heterogeneity in cGAS activity across tumors could be an important predictor of cancer prognosis and response to treatment. Indeed, our results reinforce the rationale for the use of exogenous cyclic-dinucleotides for tumor immunotherapy (Corrales et al., 2015) and suggest that NK cells could play an important role in mediating the anti-tumor effects of the treatment.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mouse Strains
All experiments were carried out with mice on the C57BL/6J background. C57BL/6J breeder mice were obtained from Jackson Laboratories. Goldenticket Sting gt/gt mutant mice were previously described (Sauer et al., 2011 , and B2m-Ly5.1 mice were bred in our facility. Sex and age-matched (6 to 14 weeks old) mice were used in experiments. Nkp46 iCre mice, which express improved CRE recombinase in NK cells (Narni-Mancinelli et al., 2011) , were generously provided by Eric Vivier. Nkp46 iCre mice were crossed to Rosa26-LSL-DTA (Jackson Laboratories) to generate NK-DTA mice, such that diphtheria toxin is expressed in nascent NK cells, resulting in NK cell-deficiency. Cgas À/À mice were generated in house using CRISPR/Cas9 technology (see below for details). All experiments were approved by the UC Berkeley Animal Care and Use Committee.
Cell Lines and Culture Conditions RMA-S, B16-BL6, RMA, RMA-RAE-1ε, MC38, THP1, and L929-ISRE cells were cultured in 5% CO 2 in RPMI containing 5% FBS (Omega scientific), 0.2 mg/mL glutamine (Sigma-Aldrich), 100 u/mL penicillin (Thermo Fisher Scientific), 100 mg/mL streptomycin (Thermo Fisher Scientific), 10 mg/mL gentamicin sulfate (Lonza), 50 mM b-mercaptoethanol (EMD Biosciences), and 20 mM HEPES (Thermo Fisher Scientific). B16-BL6-Cgas À/À cells were generated using CRISPR/Cas9 technology (see below for details). THP1
and THP1 TMEM173 À/À cells were obtained from Invivogen. MC38-GFP/Luc cells were kindly provided by Dr. Michel Dupage (UC Berkeley). All cell lines tested negative for mycoplasma contamination.
METHOD DETAILS
In Vivo Tumor Models Cells were resuspended in 100 mL of PBS, and injected subcutaneously. Tumor development and growth were monitored by caliper measurements. Tumor experiments typically included 4-6 mice per group. In vivo depletions of NK cells were done by intraperitoneal injections of 200 mg of PK136 antibody (recognizing NKR-P1C, also known as NK1.1) on day À1 prior to tumor injections, and once weekly thereafter. PK136 was purified and validated in our laboratory. NK cell-depletion was verified by flow cytometry. In Vivo Stimulation with cGAMP 200 nmol of 2ʹ3ʹ-cGAMP (made in-house), as well as 2ʹ3ʹ-cGAMP provided by Aduro Biotech, was injected intraperitoneally. 12 or 18 hr later (depending on the experiment), splenocytes and peritoneal wash cells were harvested for analysis. For intracellular cytokine staining studies, 500 mg (696 nmol) was injected either intratumorally or intraperitoneally. Tumor dissociates or peritoneal wash cells were isolated 1 hr later, and incubated for an additional 5 hr in the presence of brefeldin and monensin prior to intracellular cytokine staining.
In Vivo Rejection Assay Bone marrow cells from CD45.1 B2m À/À and CD45.1 WT mice were labeled with 10 mM CFSE or 1 mM CFSE, respectively. A mixture of 5 3 10 6 cells of each type was injected intravenously into recipient mice. Donor cell rejection was assessed 72 hr later by harvesting spleens and analyzing the percentages of CFSE high and CFSE low cells by flow cytometry.
HSV1 Infections
Age and sex-matched mice were infected intravenously with HSV-1 (ATCC), and monitored thereafter for paralysis and mortality. Moribund mice were euthanized in accordance with animal care guidelines.
Cgas Mutant Mice
Cgas mutant mice were generated using the CRISPR/Cas9 system. A gRNA was chosen to target the sequence 5 0 -TGACTCAGCGG ATTTCCTCGTGG-3 0 in the second exon. A gRNA targeting the tyrosinase gene was also included, so that a coat color change would serve to indicate mice derived from embryos in which targeting was successful. The gRNAs were in vitro transcribed and injected together with Cas9 mRNA (Trilink) into single cell embryos as previously described (Wang et al., 2013) . Several founder mice carrying frameshift mutations in the Cgas gene were identified, and a mouse carrying a 31 bp deletion was chosen. The mutation deleted the following sequence: 5 0 -CAAAAGAATTCCACGAGGAAATCCGCTGAGT-3 0 . The mouse was backcrossed for eight generations to C57BL/6J mice in order to eliminate any tyrosinase mutations or other variants, before intercrossing to generate homozygous mutant mice. Whole genome SNP analysis (UC Davis, Mouse Biology Program) was used to confirm the mice were on a pure C57BL/6 background.
Cgas
-/-Tumor Cells Cgas À/À B16-BL6 cells were generated using the CRISPR/Cas9 system. Two gRNA flanking the first exon, including the first ATG codon, were selected. The gRNA were transfected together with Cas9 mRNA (Trilink) using lipofectamine2000 (Thermo Fisher Scientific). Cells were single cell-cloned, and mutant cells were identified using PCR. The genomic target sequences used for targeting were 5 0 -GTCAGATGTCGATTGATGCC-3 0 and 5 0 -GGTGACCTTAAAGTAGTCGC-3 0 .
Plasmids, Mutagenesis, and Transduction
The retroviral Cgas expression plasmid, based on the MSCV2.2-IRES-EGFP backbone containing the complete open reading frame of mouse Cgas cDNA, was previously described (Diner et al., 2013) . The plasmid was mutagenized to generate inactive Cgas (G198A/S199A) using QuikChange Site-directed mutagenesis kit according to the manufacturer's instructions. Retroviral supernatants were generated, and transductions were performed, as previously described (Deng et al., 2015) . Briefly, 293T cells were co-transfected with plasmids encoding VSV gag/pol, Env, and pMSCV vectors using lipofectamine2000 (Thermo Fisher Scientific). Culture supernatants were collected 48 hr post-transfection, and added to pre-plated cells together with 8 mg/mL polybrene. Transduced cells were selected based on GFP expression using an Influx cell sorter.
Flow Cytometry
Flow cytometry was performed using standard protocols. Briefly, cells were stained in 50 mL FACS buffer (2% BSA, 0.02% sodium azide, 1 mM EDTA). Dead cells were excluded using Live-Dead fixable stain kit using the manufacturer protocols. Cells were incubated for 20 min with 2.4G2 hybridoma supernatant (prepared in the lab) to block FcgRII/III receptors. For intracellular staining cells were fixed using Cytofix/Cytoperm (BD). Multicolor flow cytometry was performed on one of the following machines: LSR II, or LSR Fortessa or LSR X20 (BD). Data were analyzed using FlowJo software (Tree Star). NK cells were identified as CD3-, CD19-, NKp46+ cells.
DNA Transfections and DNA Damage Induction
All transfections were carried out with lipofectamine2000 (Thermo Fisher Scientific) according to the manufacturer's instructions. B16 cells were pre-plated at 5 3 10 5 /well in 6-well plates, and transfected with HT-DNA at a final concentration of 100 mg/mL, and cultured for 6 hr, before the cells were harvested for RNA isolation. Splenocytes were plated at 10 6 /well in 96-well plates, and transfected with Vaccina 70-mer at a final concentration of 0.5 mg/mL for 4 hr. Afterward, the media was replaced with fresh media and the cells were incubated overnight. The following day media was harvested for the type I IFN bioassay. Splenocytes were also transfected with 2ʹ3ʹ-cGAMP in digitonin buffer for 30 min. Following transfection, the medium was replaced with fresh medium, and the cells were incubated for 7 hr before harvesting the culture supernatant for the type I IFN bioassay. DNA damage was induced by incubation with 50 mM ARA-C, and after 48 hr secreted type I IFN was measured using an IFN bioassay.
NK Cell Responsiveness Assay
High protein-binding flat bottom plates were pre-coated with 5 mg/mL NKG2D (MI-6) or 5 mg/mL NKp46 (29A1.4) antibody, or an isotype control antibody. Splenocytes were then incubated in the well for 5 hr in the presence of 1 mg/mL GolgiPlug (BD), 1 mg/mL GolgiStop (BD), 1,000 u/mL IL-2 (National Cancer Institute) and CD107a antibody. Following stimulation, the cells were stained for surface markers in order to identify NK cells, and intracellular IFN-g.
Quantitative RT-PCR Total RNA was isolated RNAeasy kit (QIAGEN) and reverse transcribed using iScript (Bio-Rad Laboratories) according to the manufacturer's protocol. Q-PCR was performed on a CFX96 thermocycler (Bio-Rad Laboratories) using SSO-Fast EvaGreen Supermix (Bio-Rad Laboratories). Rpl19 and Actin were used as references.
Type I IFN Bioassay L929-ISRE IFN reporter cells have been previously described (Sauer et al., 2011) . Briefly, L929-ISRE cells were pre-plated at 5 3 10 4 per well in flat bottom 96-well plates and incubated in medium for 5 hr. Following incubation, the cells were lysed in passive lysis buffer (Promega) for 5 min at room temperature. Cell lysates were incubated with firefly luciferase substrate, and luminescence was measured using SpectraMax Luminescence microplate reader (Molecular Devices).
QUANTIFICATION AND STATISTICAL ANALYSIS
Group sizes, number of replications, and explanation of the mean and error bars are provided in the figure legends. Statistical analysis was done using Prism software (GraphPad Prism software). Tumor growth experiments were analyzed with repeated-measures two-way ANOVA. Flow cytometry, QPCR, and Stimulation experiments were analyzed using two-tailed t tests or one-way ANOVA. p values less than 0.05 were considered significant. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Clinical Data Analysis
All data were obtained from TCGA using the cbioportal website (Cerami et al., 2012; Gao et al., 2013a) . Correlation of gene expression was assessed using the Spearman coefficient. For survival analysis Kaplan Meier curves were plotted comparing the patient with the highest level (upper 33%) and lowest level of particular gene (lower 33%). The curves were compared using the log-rank test.
